Table 4.

Association between immune markers and AIDS-NHL risk overall and in select subgroups

All samplesSystemicHAART UnexposedbHAART Exposed
22 cases/78 controls17 cases/62 controls13 cases/41 controls9 cases/37 controls
ORa (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
sCD231.45 (0.96–2.19)1.91 (1.14–3.23)2.00 (1.07–3.74)1.18 (0.61–2.31)
sCD277.21 (2.62–19.88)29.07 (6.72–125)6.99 (1.94–25.3)13.07 (1.87–91.7)
sCD302.64 (1.24–5.64)4.30 (1.70–10.91)3.61 (1.36–9.63)1.55 (0.46–5.30)
CXCL132.56 (1.32–4.96)5.52 (2.29–13.32)2.42 (1.05–5.58)2.15 (0.67–6.91)
IL-61.26 (0.88–1.81)1.57 (1.05–2.37)1.17 (0.69–2.00)1.37 (0.75–2.53)
CRP0.96 (0.71–1.31)1.21 (0.86–1.73)1.26 (0.86–1.87)0.64 (0.37–1.10)
  • aThe ORs represent risk of AIDS-NHL associated with one unit increase in the biomarker on the natural log scale. ORs were adjusted for CD4+ T-cell count, HIV load, and HAART exposure at each visit where the biomarker was measured, cigarette smoking, HCV infection, and education, in addition to the matching factors (time since first HIV-positive study visit, age, CD4+ T-cell count at first HIV-positive study visit, and race/ethnicity).

  • bHAART exposure at the time of the blood draw for the sample used in the immune marker assays.